The new location will help the company bring together its corporate and commercial teams with its research and development organization.
“Relocating our headquarters to Boston is an important step in Haemonetics’ transformation,” president and CEO Chris Simon said. “Our new downtown location in close proximity to the medical, technology and higher education communities that are driving the future of our industry will help foster innovation and collaboration to improve the quality of care for the patients, donors and healthcare providers who depend on our technologies.”
Haemonetics’s Boston location houses over 62,000 sq. ft in a Gold and Energy Star certified office tower, making it more sustainable and efficient that its previous Braintree, Mass. location.
“We are thrilled to welcome Haemonetics to Boston, as attracting innovative companies that demonstrate high performance and aspire to solve touch challenges in technology and healthcare will help us drive economic growth in the region,” president and CEO of the Greater Boston Chamber of Commerce James Rooney said in a news release. “Haemonetics’ addition to our diverse and collaborative business community further solidifies the city’s status as a major innovation and medtech hub.”